Table 1.
Clinical summary of 19 patients with PPL.
| Age, sex | Clinical presentation | Endocrine abnormality | Pathology | Therapy | OS (months) |
|---|---|---|---|---|---|
| 28, M [16] | HA, CN II/V | — | B-cell | Chemo + Rd | 6, alive |
| 49, M [12] | HA, CN VIII, Nys | Hypo, DI, PRL | B-cell | Ste | n.d. |
| 48, M [4] | HA, CN VI, F, S&WL, nausea | — | B-cell | Antituberculous therapy | 0.3, dead |
| 73, F [13] | HA, fatige, CN VI | Hypo, DI, PRL | B-cell | Ste + Rd | 21.6, alive |
| 53, M [11] | HA, CN VI | — | T-cell | Rd | 18, alive |
| 48, M [3] | HA, CN III/VI | — | B-cell | n.d. | n.d. |
| 67, F [9] | CN II/III | Hypo | B-cell | Rd | 4M, alive |
| 82, M [1] | HA, CN II | Hypo, DI | B-cell | Rd | n.d. |
| 65, M [10] | n.d. | Hypo, PRL | B-cell | Chemo | 0.5, alive |
| 44, M [15] | HA, CN II | — | B-cell | Chemo + MTx + Rd | n.d. |
| 86, F [31] | F, S&WL | Hypo, DI | B-cell | Chemo | 3, dead |
| 15, M [14] | F, S&WL | Hypo, DI | B-cell | Chemo + HD MTx | 17, alive |
| 74, M [8] | CN II, F, S&WL, mental status change | Hypo, | B-cell | Rd | 1.5, dead |
| 65, M [8] | CN VI, retrobulbar pain | Hypo, | B-cell | Chemo | 24, dead |
| 64, F [7] | nausea, diarrhea, edema | Hypo, DI | B-cell | Chemo + Rd | 15, dead |
| 47, M [5] | F, S&WL | Hypo, | T-cell | Chemo + i.t. MTx + Rd | 5, alive |
| 26, M [6] | HA, CN VI, F, S&WL | Hypo, PRL | NK/T-cell | Chemo + i.t. MTx + Rd | 6, dead |
| 49, F [2] | HA, F, S&WL | Hypo, DI, PRL | B-cell | MTx | 48, alive |
| 26, F [17] | HA, F, S&WL | Hypo, PRL | B-cell | — | 0.5, dead |
Hypo: anterior hypopituitarism; B-cell: B-cell lymphoma; Chemo: chemotherapy; CN: cranial nerve palsy; DI: diabetes insipidus; F, S&WL: fever, night sweat, and weight loss; HA: headache; HD: high dose; i.t.: intrathecal; MTx: methotrexate; n.d.: not described; NK: NK cell lymphoma; Nys: nystagmus; OS: overall survival; PRL: hyperprolactinemia; Rd: radiotherapy; Ste: steroid; T-cell: T-cell lymphoma; —: none.